UNSPSC 51422202: Fluorometholone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29FO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SV0CSG527L, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-6-methyl-, (6.alpha.,11.beta.)- but generally known as fluorometholone, which bears US NIH Compound Identifier 3384. European Medicines Agency schedules Fluorometholone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07720MIG.

UNSPSC 51422202 Fluorometholone is a Commodity code nominally covering ophthalmic pharmaceutical products, but recent state and local opportunities posted under this code show minimal alignment with the code's specified scope. The single representative recent opportunity — Seminole County, Florida's IFB60459723LAS — solicits naloxone and drug deactivation systems for community health support, not fluorometholone or related eye medications. A second opportunity from the Texas Health and Human Services Commission (RFI HHS0017013) explores direct-to-manufacturer prescription programs without specifying product categories. The mismatch between the code's intended scope and actual procurement activity suggests either miscoding by issuing bodies or that this Commodity code does not currently reflect active state and local demand for fluorometholone-class products.

The Seminole County opportunity represents the only concrete recent solicitation under this code. Seminole County issued an IFB on June 30, 2026, with a response deadline of July 26, 2023 (note: the deadline date appears inconsistent with the posting date), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option. The Texas RFI, posted April 3, 2026, functions as preliminary market intelligence rather than a formal procurement. Given the absence of relevant recent opportunities genuinely soliciting fluorometholone or ophthalmic pharmaceuticals under this code, pursuing business development activity here carries limited near-term prospect. Monitor for future corrections to code assignment or genuine ophthalmic pharmaceutical solicitations from state health departments and procurement offices.